A phase 3, open label, randomised, parallel group study to compare the effect on prevention and resolution of treatment related adverse events of a simplified, once daily regimen of a fixed dose combination tablet of emtricitabine and tenofovir DF [tenofovir disproxil fumarate] versus twice daily co-formulated zidovudine and lamivudine (Combivir) or zidovudine and lamivudine, in virologically suppressed, HIV infected patients taking efavirenz

Trial Profile

A phase 3, open label, randomised, parallel group study to compare the effect on prevention and resolution of treatment related adverse events of a simplified, once daily regimen of a fixed dose combination tablet of emtricitabine and tenofovir DF [tenofovir disproxil fumarate] versus twice daily co-formulated zidovudine and lamivudine (Combivir) or zidovudine and lamivudine, in virologically suppressed, HIV infected patients taking efavirenz

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Efavirenz; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine; Lamivudine/zidovudine; Zidovudine
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms SWEET
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Aug 2009 Tolerability data were published in the Journal of Acquired Immune Deficiency Syndrome.
    • 25 Jul 2007 Interim results were reported at IAS.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top